In the last 12 months, insiders at ARTIVION, INC. ($AORT) filed 367 transactions with the SEC: 2 open-market purchases totaling $53,141 and 204 sales totaling $35,457,721. Net insider sentiment: net selling.
ARTIVION, INC. operates in the Surgical & medical instruments & apparatus industry (Industrial Applications and Services sector).
Most Active Insiders
- Mackin James P (President & CEO) — 45 transactions totaling $19,327,810
- Holloway Jean F (SVP, General Counsel) — 73 transactions totaling $8,115,665
- Stanton Marshall S. (SVP, Clinical & MD Affair) — 62 transactions totaling $7,120,769
- Davis John E (Chief Commercial Officer) — 47 transactions totaling $4,151,492
- Horton Amy (VP, Chief Accounting Officer) — 44 transactions totaling $2,556,534
View all SEC Filings for ARTIVION, INC. (AORT).
Set Up your own filters →Recent Insider Transactions
| Transaction Date | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|
| March 3, 2026 | Berry Lance A | EVP, COO, CFO & Treasurer | S | Common Stock | 6316 | $37.78 | 210,827.0000 | 49,330,000 | 2.91% | 0.01% |
| March 2, 2026 | Mackin James P | President & CEO | A | Common Stock | 116948 | $0.00 | 965,162.0000 | 49,330,000 | 13.79% | 0.24% |
| March 3, 2026 | Mackin James P | President & CEO | S | Common Stock | 17887 | $37.78 | 947,275.0000 | 49,330,000 | 1.85% | 0.04% |
| March 2, 2026 | Horton Amy | VP, Chief Accounting Officer | A | Common Stock | 7475 | $0.00 | 139,989.0000 | 49,330,000 | 5.64% | 0.02% |
| March 3, 2026 | Horton Amy | VP, Chief Accounting Officer | S | Common Stock | 901 | $37.78 | 139,088.0000 | 49,330,000 | 0.64% | 0.00% |
| March 2, 2026 | Holloway Jean F | SVP, General Counsel | A | Common Stock | 27795 | $0.00 | 197,900.0000 | 49,330,000 | 16.34% | 0.06% |
| March 3, 2026 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 3843 | $37.78 | 194,057.0000 | 49,330,000 | 1.94% | 0.01% |
| March 4, 2026 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 8962 | $38.00 | 185,095.0000 | 49,330,000 | 4.62% | 0.02% |
| March 2, 2026 | Stanton Marshall S. | SVP, Clinical & MD Affair | A | Common Stock | 21838 | $0.00 | 62,246.0000 | 49,330,000 | 54.04% | 0.04% |
| March 3, 2026 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 2149 | $37.78 | 60,097.0000 | 49,330,000 | 3.45% | 0.00% |
| March 2, 2026 | Davis John E | Chief Commercial Officer | A | Common Stock | 28845 | $0.00 | 235,367.0000 | 49,330,000 | 13.97% | 0.06% |
| March 3, 2026 | Davis John E | Chief Commercial Officer | S | Common Stock | 4573 | $37.78 | 230,794.0000 | 49,330,000 | 1.94% | 0.01% |
| March 2, 2026 | Berry Lance A | EVP, COO, CFO & Treasurer | A | Common Stock | 40874 | $0.00 | 217,143.0000 | 49,330,000 | 23.19% | 0.08% |
| March 2, 2026 | Horton Amy | VP, Chief Accounting Officer | S | Common Stock | 641 | $38.02 | 132,514.0000 | 49,330,000 | 0.48% | 0.00% |
| March 2, 2026 | Berry Lance A | EVP, COO, CFO & Treasurer | S | Common Stock | 5178 | $38.02 | 176,269.0000 | 49,330,000 | 2.85% | 0.01% |
| March 2, 2026 | Davis John E | Chief Commercial Officer | S | Common Stock | 2784 | $38.02 | 206,522.0000 | 49,330,000 | 1.33% | 0.01% |
| March 2, 2026 | Mackin James P | President & CEO | S | Common Stock | 14911 | $38.02 | 848,214.0000 | 49,330,000 | 1.73% | 0.03% |
| March 2, 2026 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 1513 | $38.02 | 40,408.0000 | 49,330,000 | 3.61% | 0.00% |
| March 2, 2026 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 2183 | $38.02 | 170,105.0000 | 49,330,000 | 1.27% | 0.00% |
| Feb. 24, 2026 | Mackin James P | President & CEO | S | Common Stock | 13936 | $35.69 | 766,095.0000 | 49,330,000 | 1.79% | 0.03% |
| Feb. 23, 2026 | Horton Amy | VP, Chief Accounting Officer | S | Common Stock | 1731 | $37.59 | 128,327.0000 | 49,330,000 | 1.33% | 0.00% |
| Feb. 24, 2026 | Horton Amy | VP, Chief Accounting Officer | S | Common Stock | 830 | $35.69 | 127,497.0000 | 49,330,000 | 0.65% | 0.00% |
| Feb. 24, 2026 | Horton Amy | VP, Chief Accounting Officer | A | Common Stock | 5658 | $0.00 | 133,155.0000 | 49,330,000 | 4.44% | 0.01% |
| Feb. 23, 2026 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 2423 | $37.59 | 43,180.0000 | 49,330,000 | 5.31% | 0.00% |
| Feb. 24, 2026 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 1259 | $35.69 | 41,921.0000 | 49,330,000 | 2.92% | 0.00% |
| Feb. 23, 2026 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 3079 | $37.59 | 153,871.0000 | 49,330,000 | 1.96% | 0.01% |
| Feb. 24, 2026 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 1668 | $35.69 | 152,203.0000 | 49,330,000 | 1.08% | 0.00% |
| Feb. 24, 2026 | Holloway Jean F | SVP, General Counsel | A | Common Stock | 20085 | $0.00 | 172,288.0000 | 49,330,000 | 13.20% | 0.04% |
| Feb. 23, 2026 | Mackin James P | President & CEO | S | Common Stock | 20962 | $37.59 | 780,031.0000 | 49,330,000 | 2.62% | 0.04% |
| Feb. 24, 2026 | Mackin James P | President & CEO | A | Common Stock | 97030 | $0.00 | 863,125.0000 | 49,330,000 | 12.67% | 0.20% |
| Feb. 23, 2026 | Berry Lance A | EVP, COO, CFO & Treasurer | S | Common Stock | 4981 | $37.59 | 148,450.0000 | 49,330,000 | 3.25% | 0.01% |
| Feb. 24, 2026 | Berry Lance A | EVP, COO, CFO & Treasurer | S | Common Stock | 4485 | $35.69 | 143,965.0000 | 49,330,000 | 3.02% | 0.01% |
| Feb. 24, 2026 | Berry Lance A | EVP, COO, CFO & Treasurer | A | Common Stock | 37482 | $0.00 | 181,447.0000 | 49,330,000 | 26.04% | 0.08% |
| Feb. 23, 2026 | Davis John E | Chief Commercial Officer | S | Common Stock | 3773 | $37.59 | 190,943.0000 | 49,330,000 | 1.94% | 0.01% |
| Feb. 24, 2026 | Davis John E | Chief Commercial Officer | S | Common Stock | 2075 | $35.69 | 188,868.0000 | 49,330,000 | 1.09% | 0.00% |
| Feb. 24, 2026 | Davis John E | Chief Commercial Officer | A | Common Stock | 20438 | $0.00 | 209,306.0000 | 49,330,000 | 10.82% | 0.04% |
| June 30, 2025 | Davis John E | Chief Commercial Officer | A | Common Stock | 874 | $24.30 | 194,716.0000 | 43,432,000 | 0.45% | 0.00% |
| June 30, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | A | Common Stock | 534 | $24.30 | 45,287.0000 | 43,432,000 | 1.19% | 0.00% |
| Dec. 31, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | A | Common Stock | 316 | $26.14 | 45,603.0000 | 48,862,000 | 0.70% | 0.00% |
| Dec. 31, 2025 | Holloway Jean F | SVP, General Counsel | A | Common Stock | 228 | $26.14 | 156,950.0000 | 48,862,000 | 0.15% | 0.00% |
| June 30, 2025 | Holloway Jean F | SVP, General Counsel | A | Common Stock | 629 | $24.30 | 156,722.0000 | 43,432,000 | 0.40% | 0.00% |
| Dec. 15, 2025 | Davis John E | Chief Commercial Officer | S | Common Stock | 5000 | $45.11 | 193,842.0000 | 48,862,000 | 2.51% | 0.01% |
| Dec. 8, 2025 | Horton Amy | VP, Chief Accounting Officer | S | Common Stock | 4572 | $44.42 | 130,058.0000 | 48,862,000 | 3.40% | 0.01% |
| Dec. 3, 2025 | Mackin James P | President & CEO | M | Common Stock | 30921 | $29.62 | 831,914.0000 | 48,862,000 | 3.86% | 0.06% |
| Dec. 3, 2025 | Mackin James P | President & CEO | M | Stock Options (Right to buy) | 30921 | $0.00 | 0.0000 | 48,862,000 | 100.00% | 0.06% |
| Dec. 3, 2025 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 2048 | $45.30 | 161,360.0000 | 48,862,000 | 1.25% | 0.00% |
| Dec. 3, 2025 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 5267 | $45.30 | 156,093.0000 | 48,862,000 | 3.26% | 0.01% |
| Dec. 3, 2025 | Mackin James P | President & CEO | S | Common Stock | 30921 | $45.46 | 800,993.0000 | 48,862,000 | 3.72% | 0.06% |
| Dec. 2, 2025 | Mackin James P | President & CEO | M | Stock Options (Right to buy) | 30921 | $0.00 | 0.0000 | 48,862,000 | 100.00% | 0.06% |
| Dec. 2, 2025 | Mackin James P | President & CEO | S | Common Stock | 30921 | $45.56 | 800,993.0000 | 48,862,000 | 3.72% | 0.06% |
| Dec. 2, 2025 | Mackin James P | President & CEO | M | Common Stock | 30921 | $29.62 | 831,914.0000 | 48,862,000 | 3.86% | 0.06% |
| Dec. 1, 2025 | Horton Amy | VP, Chief Accounting Officer | G | Common Stock | 750 | $0.00 | 134,630.0000 | 48,862,000 | 0.55% | 0.00% |
| Nov. 21, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 8370 | $45.35 | 44,753.0000 | 48,862,000 | 15.76% | 0.02% |
| Nov. 21, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | M | Common Stock | 27075 | $11.03 | 71,828.0000 | 48,862,000 | 60.50% | 0.06% |
| Nov. 21, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 5715 | $45.35 | 44,753.0000 | 48,862,000 | 11.32% | 0.01% |
| Nov. 21, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 14586 | $44.92 | 50,468.0000 | 48,862,000 | 22.42% | 0.03% |
| Nov. 21, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | M | Common Stock | 20301 | $18.44 | 65,054.0000 | 48,862,000 | 45.36% | 0.04% |
| Nov. 20, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | M | Stock Options (Right to buy) | 1355 | $0.00 | 27,075.0000 | 48,862,000 | 4.77% | 0.00% |
| Nov. 20, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | M | Stock Options (Right to buy) | 2033 | $0.00 | 20,301.0000 | 48,862,000 | 9.10% | 0.00% |
| Nov. 20, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 1355 | $44.28 | 44,753.0000 | 48,862,000 | 2.94% | 0.00% |
| Nov. 20, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | M | Common Stock | 1355 | $11.03 | 46,108.0000 | 48,862,000 | 3.03% | 0.00% |
| Nov. 20, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 2033 | $44.32 | 44,753.0000 | 48,862,000 | 4.35% | 0.00% |
| Nov. 20, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | M | Common Stock | 2033 | $18.44 | 46,786.0000 | 48,862,000 | 4.54% | 0.00% |
| Nov. 20, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 11888 | $44.14 | 44,753.0000 | 48,862,000 | 20.99% | 0.02% |
| Nov. 21, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | M | Stock Options (Right to buy) | 27075 | $0.00 | 0.0000 | 48,862,000 | 100.00% | 0.06% |
| Nov. 21, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | M | Stock Options (Right to buy) | 20301 | $0.00 | 0.0000 | 48,862,000 | 100.00% | 0.04% |
| Nov. 21, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 18705 | $44.91 | 53,123.0000 | 48,862,000 | 26.04% | 0.04% |
| Nov. 18, 2025 | Hoff Elizabeth A | Director | S | Common Stock | 4200 | $45.10 | 27,189.0000 | 48,862,000 | 13.38% | 0.01% |
| Nov. 17, 2025 | Davis John E | Chief Commercial Officer | M | Stock Options (Right to buy) | 6394 | $0.00 | 0.0000 | 48,862,000 | 100.00% | 0.01% |
| Nov. 14, 2025 | Holloway Jean F | SVP, General Counsel | M | Common Stock | 6393 | $29.62 | 169,801.0000 | 48,862,000 | 3.91% | 0.01% |
| Nov. 14, 2025 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 6393 | $45.00 | 163,408.0000 | 48,862,000 | 3.76% | 0.01% |
| Nov. 17, 2025 | Horton Amy | VP, Chief Accounting Officer | S | Common Stock | 6000 | $45.73 | 135,380.0000 | 48,862,000 | 4.24% | 0.01% |
| Nov. 17, 2025 | Holloway Jean F | SVP, General Counsel | M | Common Stock | 6394 | $29.62 | 169,802.0000 | 48,862,000 | 3.91% | 0.01% |
| Nov. 17, 2025 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 6394 | $45.17 | 163,408.0000 | 48,862,000 | 3.77% | 0.01% |
| Nov. 14, 2025 | Holloway Jean F | SVP, General Counsel | M | Stock Options (Right to buy) | 6393 | $0.00 | 0.0000 | 48,862,000 | 100.00% | 0.01% |
| Nov. 17, 2025 | Holloway Jean F | SVP, General Counsel | M | Stock Options (Right to buy) | 6394 | $0.00 | 0.0000 | 48,862,000 | 100.00% | 0.01% |
| Nov. 14, 2025 | Davis John E | Chief Commercial Officer | M | Common Stock | 6393 | $29.62 | 205,235.0000 | 48,862,000 | 3.22% | 0.01% |
| Nov. 14, 2025 | Davis John E | Chief Commercial Officer | S | Common Stock | 6393 | $44.67 | 198,842.0000 | 48,862,000 | 3.11% | 0.01% |
| Nov. 17, 2025 | Davis John E | Chief Commercial Officer | M | Common Stock | 6394 | $29.62 | 205,236.0000 | 48,862,000 | 3.22% | 0.01% |
| Nov. 17, 2025 | Davis John E | Chief Commercial Officer | S | Common Stock | 6394 | $45.17 | 198,842.0000 | 48,862,000 | 3.12% | 0.01% |
| Nov. 14, 2025 | Davis John E | Chief Commercial Officer | M | Stock Options (Right to buy) | 6393 | $0.00 | 0.0000 | 48,862,000 | 100.00% | 0.01% |
| Nov. 13, 2025 | Horton Amy | VP, Chief Accounting Officer | S | Common Stock | 3482 | $45.86 | 141,380.0000 | 48,862,000 | 2.40% | 0.01% |
| Nov. 13, 2025 | Mackin James P | President & CEO | S | Common Stock | 34210 | $45.86 | 800,993.0000 | 48,862,000 | 4.10% | 0.07% |
| Nov. 13, 2025 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 5761 | $45.86 | 163,408.0000 | 48,862,000 | 3.41% | 0.01% |
| Nov. 13, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 4993 | $45.86 | 56,641.0000 | 48,862,000 | 8.10% | 0.01% |
| Nov. 13, 2025 | Davis John E | Chief Commercial Officer | S | Common Stock | 6563 | $45.86 | 198,842.0000 | 48,862,000 | 3.20% | 0.01% |
| Nov. 11, 2025 | Holloway Jean F | SVP, General Counsel | M | Stock Options (Right to buy) | 10000 | $0.00 | 0.0000 | 48,862,000 | 100.00% | 0.02% |
| Nov. 10, 2025 | Mackin James P | President & CEO | S | Common Stock | 17580 | $44.62 | 835,203.0000 | 48,862,000 | 2.06% | 0.04% |
| Nov. 10, 2025 | Horton Amy | VP, Chief Accounting Officer | S | Common Stock | 1789 | $44.62 | 144,862.0000 | 48,862,000 | 1.22% | 0.00% |
| Nov. 10, 2025 | Davis John E | Chief Commercial Officer | S | Common Stock | 3373 | $44.62 | 205,405.0000 | 48,862,000 | 1.62% | 0.01% |
| Nov. 10, 2025 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 2960 | $44.62 | 169,169.0000 | 48,862,000 | 1.72% | 0.01% |
| Nov. 11, 2025 | Holloway Jean F | SVP, General Counsel | M | Common Stock | 10000 | $11.03 | 179,169.0000 | 48,862,000 | 5.91% | 0.02% |
| Nov. 10, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 2566 | $44.62 | 61,634.0000 | 48,862,000 | 4.00% | 0.01% |
| Nov. 11, 2025 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 10000 | $46.18 | 169,169.0000 | 48,862,000 | 5.58% | 0.02% |
| Aug. 27, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | M | Stock Option (Right to Buy) | 18200 | $0.00 | 0.0000 | 48,592,000 | 100.00% | 0.04% |
| Aug. 27, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | M | Common Stock | 18200 | $11.03 | 82,400.0000 | 48,592,000 | 28.35% | 0.04% |
| Aug. 27, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 18200 | $44.02 | 64,200.0000 | 48,592,000 | 22.09% | 0.04% |
| Aug. 25, 2025 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 10000 | $44.37 | 172,129.0000 | 48,592,000 | 5.49% | 0.02% |
| Aug. 25, 2025 | Holloway Jean F | SVP, General Counsel | M | Common Stock | 10000 | $11.03 | 182,129.0000 | 48,592,000 | 5.81% | 0.02% |
| Aug. 25, 2025 | Holloway Jean F | SVP, General Counsel | M | Stock Option (Right to Buy) | 10000 | $0.00 | 0.0000 | 48,592,000 | 100.00% | 0.02% |
| Aug. 15, 2025 | Mackin James P | President & CEO | S | Common Stock | 12500 | $42.32 | 852,783.0000 | 48,592,000 | 1.44% | 0.03% |
| Aug. 12, 2025 | Davis John E | Chief Commercial Officer | M | Stock Options (Right to buy) | 10802 | $0.00 | 0.0000 | 48,592,000 | 100.00% | 0.02% |
| Aug. 12, 2025 | Holloway Jean F | SVP, General Counsel | M | Common Stock | 16975 | $26.24 | 195,485.0000 | 48,592,000 | 9.51% | 0.03% |
| Aug. 12, 2025 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 6381 | $43.02 | 172,129.0000 | 48,592,000 | 3.57% | 0.01% |
| Aug. 12, 2025 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 16975 | $43.01 | 178,510.0000 | 48,592,000 | 8.68% | 0.03% |
| Aug. 12, 2025 | Holloway Jean F | SVP, General Counsel | M | Stock Option(Right to Buy) | 16975 | $0.00 | 0.0000 | 48,592,000 | 100.00% | 0.03% |
| Aug. 12, 2025 | Davis John E | Chief Commercial Officer | M | Common Stock | 10802 | $26.24 | 219,580.0000 | 48,592,000 | 5.17% | 0.02% |
| Aug. 12, 2025 | Davis John E | Chief Commercial Officer | S | Common Stock | 10802 | $43.67 | 208,778.0000 | 48,592,000 | 4.92% | 0.02% |
| Aug. 8, 2025 | Horton Amy | VP, Chief Accounting Officer | S | Common Stock | 7992 | $38.49 | 146,651.0000 | 48,592,000 | 5.17% | 0.02% |
| Aug. 8, 2025 | Horton Amy | VP, Chief Accounting Officer | M | Stock Option (Right to Buy) | 7992 | $0.00 | 0.0000 | 48,592,000 | 100.00% | 0.02% |
| Aug. 8, 2025 | Horton Amy | VP, Chief Accounting Officer | M | Common Stock | 7992 | $29.62 | 154,643.0000 | 48,592,000 | 5.45% | 0.02% |
| June 17, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 1236 | $29.50 | 64,200.0000 | 43,432,000 | 1.89% | 0.00% |
| June 17, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 13764 | $29.50 | 65,436.0000 | 43,432,000 | 17.38% | 0.03% |
| June 13, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 1826 | $28.43 | 79,200.0000 | 43,432,000 | 2.25% | 0.00% |
| June 13, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 14306 | $28.42 | 81,026.0000 | 43,432,000 | 15.01% | 0.03% |
| June 13, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 1253 | $28.47 | 95,332.0000 | 43,432,000 | 1.30% | 0.00% |
| June 13, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 8747 | $28.46 | 96,585.0000 | 43,432,000 | 8.30% | 0.02% |
| May 22, 2025 | Salveson Jon W | Director | A | Common Stock | 6325 | $0.00 | 129,840.0000 | 43,432,000 | 5.12% | 0.01% |
| May 22, 2025 | Hoff Elizabeth A | Director | A | Common Stock | 6325 | $0.00 | 31,389.0000 | 43,432,000 | 25.24% | 0.01% |
| May 22, 2025 | Burbank Jeffrey H | Director | A | Common Stock | 6325 | $0.00 | 53,796.0000 | 43,432,000 | 13.32% | 0.01% |
| May 22, 2025 | Bullock James | Director | A | Common Stock | 6325 | $0.00 | 68,647.0000 | 43,432,000 | 10.15% | 0.01% |
| May 23, 2025 | SEMEDO ANTHONY B. | Director | S | Common Stock | 2600 | $28.47 | 33,059.0000 | 43,432,000 | 7.29% | 0.01% |
| May 27, 2025 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 8748 | $29.00 | 178,510.0000 | 43,432,000 | 4.67% | 0.02% |
| May 22, 2025 | Borgstrom Marna P | Director | A | Common Stock | 6325 | $0.00 | 49,088.0000 | 43,432,000 | 14.79% | 0.01% |
| May 22, 2025 | BEVEVINO DANIEL J | Director | A | Common Stock | 6325 | $0.00 | 150,061.0000 | 43,432,000 | 4.40% | 0.01% |
| May 22, 2025 | ACKERMAN THOMAS F | Director | A | Common Stock | 6325 | $0.00 | 149,896.0000 | 43,432,000 | 4.41% | 0.01% |
| May 23, 2025 | SEMEDO ANTHONY B. | Director | S | Common Stock | 2600 | $28.47 | 39,384.0000 | 43,432,000 | 6.19% | 0.01% |
| May 22, 2025 | SEMEDO ANTHONY B. | Director | A | Common Stock | 6325 | $0.00 | 41,984.0000 | 43,432,000 | 17.74% | 0.01% |
| May 21, 2025 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 9926 | $29.00 | 187,258.0000 | 43,432,000 | 5.03% | 0.02% |
| May 9, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 4811 | $29.13 | 105,332.0000 | 43,432,000 | 4.37% | 0.01% |
| May 9, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 5737 | $29.13 | 110,143.0000 | 43,432,000 | 4.95% | 0.01% |
| March 11, 2025 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 18020 | $23.61 | 197,184.0000 | 43,432,000 | 8.37% | 0.04% |
| March 11, 2025 | Holloway Jean F | SVP, General Counsel | M | Common Stock | 19092 | $21.55 | 215,204.0000 | 43,432,000 | 9.74% | 0.04% |
| March 11, 2025 | Davis John E | Chief Commercial Officer | M | Common Stock | 15910 | $21.55 | 223,878.0000 | 43,432,000 | 7.65% | 0.04% |
| March 11, 2025 | Holloway Jean F | SVP, General Counsel | M | Stock Options (Right to buy) | 19092 | $0.00 | 0.0000 | 43,432,000 | 100.00% | 0.04% |
| March 11, 2025 | Davis John E | Chief Commercial Officer | S | Common Stock | 15100 | $23.61 | 208,778.0000 | 43,432,000 | 6.74% | 0.03% |
| March 11, 2025 | Davis John E | Chief Commercial Officer | M | Stock Options (Right to buy) | 15910 | $0.00 | 0.0000 | 43,432,000 | 100.00% | 0.04% |
| March 6, 2025 | Davis John E | Chief Commercial Officer | S | Common Stock | 2618 | $24.80 | 207,968.0000 | 43,432,000 | 1.24% | 0.01% |
| March 6, 2025 | Mackin James P | President & CEO | A | Common Stock | 115701 | $0.00 | 878,107.0000 | 43,432,000 | 15.18% | 0.27% |
| March 6, 2025 | Mackin James P | President & CEO | S | Common Stock | 17739 | $24.80 | 860,368.0000 | 43,432,000 | 2.02% | 0.04% |
| March 6, 2025 | Mackin James P | President & CEO | M | Common Stock | 75615 | $21.55 | 935,983.0000 | 43,432,000 | 8.79% | 0.17% |
| March 6, 2025 | Mackin James P | President & CEO | S | Common Stock | 70700 | $24.76 | 865,283.0000 | 43,432,000 | 7.55% | 0.16% |
| March 6, 2025 | Mackin James P | President & CEO | M | Stock Options (Right to buy) | 75615 | $0.00 | 0.0000 | 43,432,000 | 100.00% | 0.17% |
| March 6, 2025 | Horton Amy | VP, Chief Accounting Officer | A | Common Stock | 10261 | $0.00 | 147,699.0000 | 43,432,000 | 7.47% | 0.02% |
| March 6, 2025 | Horton Amy | VP, Chief Accounting Officer | S | Common Stock | 1048 | $24.80 | 146,651.0000 | 43,432,000 | 0.71% | 0.00% |
| March 6, 2025 | Berry Lance A | Executive VP, CFO | A | Common Stock | 48100 | $0.00 | 158,340.0000 | 43,432,000 | 43.63% | 0.11% |
| March 6, 2025 | Berry Lance A | Executive VP, CFO | S | Common Stock | 4909 | $24.80 | 153,431.0000 | 43,432,000 | 3.10% | 0.01% |
| March 6, 2025 | Davis John E | Chief Commercial Officer | A | Common Stock | 25654 | $0.00 | 210,586.0000 | 43,432,000 | 13.87% | 0.06% |
| March 6, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | A | Common Stock | 19240 | $0.00 | 117,483.0000 | 43,432,000 | 19.58% | 0.04% |
| March 6, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 1603 | $24.80 | 115,880.0000 | 43,432,000 | 1.36% | 0.00% |
| March 6, 2025 | Holloway Jean F | SVP, General Counsel | A | Common Stock | 25493 | $0.00 | 198,236.0000 | 43,432,000 | 14.76% | 0.06% |
| March 6, 2025 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 2124 | $24.80 | 196,112.0000 | 43,432,000 | 1.07% | 0.00% |
| March 5, 2025 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 472 | $25.29 | 172,743.0000 | 43,432,000 | 0.27% | 0.00% |
| March 5, 2025 | SEMEDO ANTHONY B. | Director | P | Common Stock | 600 | $25.25 | 36,259.0000 | 43,432,000 | 1.68% | 0.00% |
| March 5, 2025 | SEMEDO ANTHONY B. | Director | P | Common Stock | 1500 | $25.33 | 36,259.0000 | 43,432,000 | 4.32% | 0.00% |
| Feb. 28, 2025 | Mackin James P | President & CEO | A | Common Stock | 98524 | $0.00 | 762,406.0000 | 43,432,000 | 14.84% | 0.23% |
| Feb. 28, 2025 | Davis John E | Chief Commercial Officer | A | Common Stock | 24301 | $0.00 | 184,932.0000 | 43,432,000 | 15.13% | 0.06% |
| Feb. 28, 2025 | Berry Lance A | Executive VP, CFO | A | Common Stock | 34435 | $0.00 | 110,240.0000 | 43,432,000 | 45.43% | 0.08% |
| Feb. 28, 2025 | Holloway Jean F | SVP, General Counsel | A | Common Stock | 23416 | $0.00 | 173,215.0000 | 43,432,000 | 15.63% | 0.05% |
| Feb. 28, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | A | Common Stock | 18398 | $0.00 | 98,243.0000 | 43,432,000 | 23.04% | 0.04% |
| Feb. 28, 2025 | Horton Amy | VP, Chief Accounting Officer | A | Common Stock | 6297 | $0.00 | 137,438.0000 | 43,432,000 | 4.80% | 0.01% |
| Feb. 24, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 2299 | $27.31 | 82,233.0000 | 43,432,000 | 2.72% | 0.01% |
| Feb. 24, 2025 | Berry Lance A | Executive VP, CFO | S | Common Stock | 3259 | $27.31 | 75,805.0000 | 43,432,000 | 4.12% | 0.01% |
| Feb. 24, 2025 | Davis John E | Chief Commercial Officer | S | Common Stock | 2035 | $27.31 | 160,631.0000 | 43,432,000 | 1.25% | 0.00% |
| Feb. 24, 2025 | Davis John E | Chief Commercial Officer | S | Common Stock | 985 | $27.31 | 162,666.0000 | 43,432,000 | 0.60% | 0.00% |
| Feb. 24, 2025 | Davis John E | Chief Commercial Officer | S | Common Stock | 591 | $27.31 | 163,651.0000 | 43,432,000 | 0.36% | 0.00% |
| Feb. 24, 2025 | Davis John E | Chief Commercial Officer | S | Common Stock | 2846 | $27.31 | 164,242.0000 | 43,432,000 | 1.70% | 0.01% |
| Feb. 24, 2025 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 1650 | $27.31 | 149,799.0000 | 43,432,000 | 1.09% | 0.00% |
| Feb. 24, 2025 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 810 | $27.31 | 151,449.0000 | 43,432,000 | 0.53% | 0.00% |
| Feb. 24, 2025 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 490 | $27.31 | 152,259.0000 | 43,432,000 | 0.32% | 0.00% |
| Feb. 24, 2025 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 2385 | $27.31 | 152,749.0000 | 43,432,000 | 1.54% | 0.01% |
| Feb. 24, 2025 | Horton Amy | VP, Chief Accounting Officer | S | Common Stock | 1706 | $27.31 | 132,758.0000 | 43,432,000 | 1.27% | 0.00% |
| Feb. 24, 2025 | Horton Amy | VP, Chief Accounting Officer | S | Common Stock | 318 | $27.31 | 131,626.0000 | 43,432,000 | 0.24% | 0.00% |
| Feb. 24, 2025 | Horton Amy | VP, Chief Accounting Officer | S | Common Stock | 814 | $27.31 | 131,944.0000 | 43,432,000 | 0.61% | 0.00% |
| Feb. 24, 2025 | Horton Amy | VP, Chief Accounting Officer | S | Common Stock | 485 | $27.31 | 131,141.0000 | 43,432,000 | 0.37% | 0.00% |
| Feb. 24, 2025 | Mackin James P | President & CEO | S | Common Stock | 16664 | $27.31 | 689,374.0000 | 43,432,000 | 2.36% | 0.04% |
| Feb. 24, 2025 | Mackin James P | President & CEO | S | Common Stock | 13784 | $27.31 | 675,590.0000 | 43,432,000 | 2.00% | 0.03% |
| Feb. 24, 2025 | Mackin James P | President & CEO | S | Common Stock | 6812 | $27.31 | 668,778.0000 | 43,432,000 | 1.01% | 0.02% |
| Feb. 24, 2025 | Mackin James P | President & CEO | S | Common Stock | 4896 | $27.31 | 663,882.0000 | 43,432,000 | 0.73% | 0.01% |
| Feb. 24, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 1246 | $27.31 | 79,845.0000 | 43,432,000 | 1.54% | 0.00% |
| Feb. 24, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 672 | $27.31 | 81,091.0000 | 43,432,000 | 0.82% | 0.00% |
| Feb. 24, 2025 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 470 | $27.31 | 81,763.0000 | 43,432,000 | 0.57% | 0.00% |
| June 30, 2024 | Holloway Jean F | SVP, General Counsel | A | Common Stock | 977 | $15.20 | 154,839.0000 | 42,569,000 | 0.63% | 0.00% |
| Dec. 31, 2024 | Holloway Jean F | SVP, General Counsel | A | Common Stock | 295 | $21.63 | 155,134.0000 | 43,392,000 | 0.19% | 0.00% |
| Dec. 31, 2024 | Stanton Marshall S. | SVP, Clinical & MD Affair | A | Common Stock | 381 | $21.63 | 84,532.0000 | 43,392,000 | 0.45% | 0.00% |
| June 30, 2024 | Stanton Marshall S. | SVP, Clinical & MD Affair | A | Common Stock | 855 | $15.20 | 84,151.0000 | 42,569,000 | 1.03% | 0.00% |
| June 30, 2024 | Davis John E | Chief Commercial Officer | A | Common Stock | 1398 | $15.20 | 167,088.0000 | 42,569,000 | 0.84% | 0.00% |
| Dec. 12, 2024 | Horton Amy | VP, Chief Accounting Officer | G | Common Stock | 1100 | $0.00 | 134,464.0000 | 43,392,000 | 0.81% | 0.00% |
| Dec. 11, 2024 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 4035 | $30.25 | 157,897.0000 | 43,392,000 | 2.49% | 0.01% |
| Dec. 11, 2024 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 4035 | $30.00 | 153,862.0000 | 43,392,000 | 2.56% | 0.01% |
| Dec. 6, 2024 | Horton Amy | VP, Chief Accounting Officer | S | Common Stock | 4425 | $29.05 | 135,564.0000 | 43,392,000 | 3.16% | 0.01% |
| Dec. 6, 2024 | Horton Amy | VP, Chief Accounting Officer | S | Common Stock | 4329 | $29.66 | 135,660.0000 | 43,392,000 | 3.09% | 0.01% |
| Dec. 4, 2024 | GREEN ANDREW M | VP Regulatory | S | Common Stock | 7618 | $30.00 | 33,503.0000 | 43,392,000 | 18.53% | 0.02% |
| Oct. 1, 2024 | Horton Amy | VP, Chief Accounting Officer | M | Stock Option (Right to Buy) | 12430 | $0.00 | 0.0000 | 43,392,000 | 100.00% | 0.03% |
| Oct. 1, 2024 | Horton Amy | VP, Chief Accounting Officer | S | Common Stock | 12430 | $26.18 | 139,989.0000 | 43,392,000 | 8.16% | 0.03% |
| Oct. 1, 2024 | Horton Amy | VP, Chief Accounting Officer | M | Common Stock | 12430 | $21.55 | 152,419.0000 | 43,392,000 | 8.88% | 0.03% |
| Aug. 26, 2024 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 3167 | $26.55 | 161,932.0000 | 43,279,000 | 1.92% | 0.01% |
| Aug. 16, 2024 | Getz Matthew A | VP, Human Resources | S | Common Stock | 6858 | $25.31 | 36,678.0000 | 43,279,000 | 15.75% | 0.02% |
| Aug. 16, 2024 | Getz Matthew A | VP, Human Resources | S | Common Stock | 2562 | $25.31 | 34,116.0000 | 43,279,000 | 6.99% | 0.01% |
| Aug. 15, 2024 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 2383 | $25.76 | 165,099.0000 | 43,279,000 | 1.42% | 0.01% |
| Aug. 13, 2024 | SEMEDO ANTHONY B. | Director | S | Common Stock | 9709 | $24.99 | 34,159.0000 | 43,279,000 | 22.13% | 0.02% |
| May 30, 2024 | SEMEDO ANTHONY B. | Director | A | Common Stock | 6289 | $0.00 | 43,868.0000 | 42,569,000 | 16.74% | 0.01% |
| May 30, 2024 | Borgstrom Marna P | Director | A | Common Stock | 6289 | $0.00 | 42,763.0000 | 42,569,000 | 17.24% | 0.01% |
| May 30, 2024 | Burbank Jeffrey H | Director | A | Common Stock | 6289 | $0.00 | 47,471.0000 | 42,569,000 | 15.27% | 0.01% |
| May 30, 2024 | Bullock James | Director | A | Common Stock | 6289 | $0.00 | 62,322.0000 | 42,569,000 | 11.22% | 0.01% |
| May 30, 2024 | Salveson Jon W | Director | A | Common Stock | 6289 | $0.00 | 123,515.0000 | 42,569,000 | 5.36% | 0.01% |
| May 30, 2024 | BEVEVINO DANIEL J | Director | A | Common Stock | 6289 | $0.00 | 143,736.0000 | 42,569,000 | 4.58% | 0.01% |
| May 30, 2024 | ACKERMAN THOMAS F | Director | A | Common Stock | 6289 | $0.00 | 143,571.0000 | 42,569,000 | 4.58% | 0.01% |
| May 30, 2024 | Hoff Elizabeth A | Director | A | Common Stock | 6289 | $0.00 | 25,064.0000 | 42,569,000 | 33.50% | 0.01% |
| May 10, 2024 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 1250 | $23.42 | 167,482.0000 | 42,569,000 | 0.74% | 0.00% |
| May 9, 2024 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 979 | $23.79 | 168,732.0000 | 42,569,000 | 0.58% | 0.00% |
| March 20, 2024 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 2183 | $20.39 | 83,296.0000 | 42,569,000 | 2.55% | 0.01% |
| March 15, 2024 | GREEN ANDREW M | VP Regulatory | S | Common Stock | 1462 | $20.00 | 41,121.0000 | 42,569,000 | 3.43% | 0.00% |
| March 14, 2024 | GREEN ANDREW M | VP Regulatory | S | Common Stock | 3994 | $20.00 | 42,583.0000 | 42,569,000 | 8.58% | 0.01% |
| Feb. 26, 2024 | Mackin James P | President & CEO | S | Common Stock | 12968 | $20.27 | 696,253.0000 | 42,569,000 | 1.83% | 0.03% |
| March 1, 2024 | Horton Amy | VP, Chief Accounting Officer | A | Common Stock | 3578 | $0.00 | 141,141.0000 | 42,569,000 | 2.60% | 0.01% |
| March 5, 2024 | Mackin James P | President & CEO | S | Common Stock | 13996 | $18.72 | 706,038.0000 | 42,569,000 | 1.94% | 0.03% |
| March 1, 2024 | Mackin James P | President & CEO | A | Common Stock | 28618 | $0.00 | 720,034.0000 | 42,569,000 | 4.14% | 0.07% |
| March 5, 2024 | Davis John E | Chief Commercial Officer | S | Common Stock | 2022 | $18.72 | 165,690.0000 | 42,569,000 | 1.21% | 0.00% |
| March 1, 2024 | Davis John E | Chief Commercial Officer | A | Common Stock | 5724 | $0.00 | 167,712.0000 | 42,569,000 | 3.53% | 0.01% |
| March 5, 2024 | Getz Matthew A | VP, Human Resources | S | Common Stock | 1157 | $18.72 | 48,536.0000 | 42,569,000 | 2.33% | 0.00% |
| March 1, 2024 | Getz Matthew A | VP, Human Resources | A | Common Stock | 3578 | $0.00 | 49,693.0000 | 42,569,000 | 7.76% | 0.01% |
| March 5, 2024 | GREEN ANDREW M | VP Regulatory | S | Common Stock | 1160 | $18.72 | 46,577.0000 | 42,569,000 | 2.43% | 0.00% |
| March 1, 2024 | GREEN ANDREW M | VP Regulatory | A | Common Stock | 3578 | $0.00 | 47,737.0000 | 42,569,000 | 8.10% | 0.01% |
| March 5, 2024 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 2380 | $18.72 | 169,711.0000 | 42,569,000 | 1.38% | 0.01% |
| March 5, 2024 | Maney Rochelle L. | VP, Quality | S | Common Stock | 1157 | $18.72 | 46,569.0000 | 42,569,000 | 2.42% | 0.00% |
| March 1, 2024 | Maney Rochelle L. | VP, Quality | A | Common Stock | 3578 | $0.00 | 47,726.0000 | 42,569,000 | 8.10% | 0.01% |
| Feb. 27, 2024 | Getz Matthew A | VP, Human Resources | S | Common Stock | 325 | $19.83 | 46,115.0000 | 42,569,000 | 0.70% | 0.00% |
| Feb. 26, 2024 | Getz Matthew A | VP, Human Resources | S | Common Stock | 1112 | $20.27 | 46,440.0000 | 42,569,000 | 2.34% | 0.00% |
| Feb. 23, 2024 | Getz Matthew A | VP, Human Resources | A | Common Stock | 7412 | $0.00 | 47,552.0000 | 42,569,000 | 18.47% | 0.02% |
| Feb. 26, 2024 | Getz Matthew A | VP, Human Resources | S | Common Stock | 1168 | $20.27 | 40,140.0000 | 42,569,000 | 2.83% | 0.00% |
| Feb. 23, 2024 | Getz Matthew A | VP, Human Resources | A | Common Stock | 3366 | $0.00 | 41,308.0000 | 42,569,000 | 8.87% | 0.01% |
| March 1, 2024 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 1506 | $18.72 | 85,479.0000 | 42,569,000 | 1.73% | 0.00% |
| March 1, 2024 | Stanton Marshall S. | SVP, Clinical & MD Affair | A | Common Stock | 5724 | $0.00 | 86,985.0000 | 42,569,000 | 7.04% | 0.01% |
| March 5, 2024 | Horton Amy | VP, Chief Accounting Officer | S | Common Stock | 1152 | $18.72 | 139,989.0000 | 42,569,000 | 0.82% | 0.00% |
| March 1, 2024 | Holloway Jean F | SVP, General Counsel | A | Common Stock | 5724 | $0.00 | 172,091.0000 | 42,569,000 | 3.44% | 0.01% |
| Feb. 27, 2024 | Mackin James P | President & CEO | S | Common Stock | 4837 | $19.83 | 691,416.0000 | 42,569,000 | 0.69% | 0.01% |
| March 12, 2024 | Getz Matthew A | VP, Human Resources | S | Common Stock | 5000 | $19.94 | 43,536.0000 | 42,569,000 | 10.30% | 0.01% |
| Feb. 26, 2024 | GREEN ANDREW M | VP Regulatory | S | Common Stock | 1168 | $20.27 | 38,865.0000 | 42,569,000 | 2.92% | 0.00% |
| Feb. 23, 2024 | GREEN ANDREW M | VP Regulatory | A | Common Stock | 6914 | $0.00 | 45,779.0000 | 42,569,000 | 17.79% | 0.02% |
| Feb. 26, 2024 | GREEN ANDREW M | VP Regulatory | S | Common Stock | 1199 | $20.27 | 44,580.0000 | 42,569,000 | 2.62% | 0.00% |
| Feb. 23, 2024 | Davis John E | Chief Commercial Officer | A | Common Stock | 5386 | $0.00 | 153,279.0000 | 42,569,000 | 3.64% | 0.01% |
| Feb. 26, 2024 | Davis John E | Chief Commercial Officer | S | Common Stock | 1586 | $20.27 | 151,711.0000 | 42,569,000 | 1.03% | 0.00% |
| Feb. 23, 2024 | Davis John E | Chief Commercial Officer | A | Common Stock | 12736 | $0.00 | 164,447.0000 | 42,569,000 | 8.39% | 0.03% |
| Feb. 26, 2024 | Davis John E | Chief Commercial Officer | S | Common Stock | 1875 | $20.27 | 162,572.0000 | 42,569,000 | 1.14% | 0.00% |
| Feb. 27, 2024 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 465 | $19.83 | 81,261.0000 | 42,569,000 | 0.57% | 0.00% |
| Feb. 27, 2024 | Maney Rochelle L. | VP, Quality | S | Common Stock | 370 | $19.83 | 44,148.0000 | 42,569,000 | 0.83% | 0.00% |
| Feb. 27, 2024 | GREEN ANDREW M | VP Regulatory | S | Common Stock | 421 | $19.83 | 44,159.0000 | 42,569,000 | 0.94% | 0.00% |
| Feb. 27, 2024 | Horton Amy | VP, Chief Accounting Officer | S | Common Stock | 325 | $19.83 | 137,563.0000 | 42,569,000 | 0.24% | 0.00% |
| Feb. 27, 2024 | Davis John E | Chief Commercial Officer | S | Common Stock | 584 | $19.83 | 161,988.0000 | 42,569,000 | 0.36% | 0.00% |
| Feb. 23, 2024 | Mackin James P | President & CEO | A | Common Stock | 40404 | $0.00 | 668,441.0000 | 42,569,000 | 6.43% | 0.09% |
| Feb. 26, 2024 | Mackin James P | President & CEO | S | Common Stock | 17868 | $20.27 | 650,573.0000 | 42,569,000 | 2.67% | 0.04% |
| Feb. 23, 2024 | Mackin James P | President & CEO | A | Common Stock | 58648 | $0.00 | 709,221.0000 | 42,569,000 | 9.01% | 0.14% |
| Feb. 27, 2024 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 485 | $19.83 | 166,367.0000 | 42,569,000 | 0.29% | 0.00% |
| Feb. 23, 2024 | Horton Amy | VP, Chief Accounting Officer | A | Common Stock | 3366 | $0.00 | 133,604.0000 | 42,569,000 | 2.58% | 0.01% |
| Feb. 26, 2024 | Horton Amy | VP, Chief Accounting Officer | S | Common Stock | 1168 | $20.27 | 132,436.0000 | 42,569,000 | 0.87% | 0.00% |
| Feb. 23, 2024 | Horton Amy | VP, Chief Accounting Officer | A | Common Stock | 6418 | $0.00 | 138,854.0000 | 42,569,000 | 4.85% | 0.02% |
| Feb. 26, 2024 | Horton Amy | VP, Chief Accounting Officer | S | Common Stock | 966 | $20.27 | 137,888.0000 | 42,569,000 | 0.70% | 0.00% |
| Feb. 23, 2024 | Stanton Marshall S. | SVP, Clinical & MD Affair | A | Common Stock | 5386 | $0.00 | 74,089.0000 | 42,569,000 | 7.84% | 0.01% |
| Feb. 26, 2024 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 1576 | $20.27 | 72,513.0000 | 42,569,000 | 2.13% | 0.00% |
| Feb. 23, 2024 | Stanton Marshall S. | SVP, Clinical & MD Affair | A | Common Stock | 10644 | $0.00 | 83,157.0000 | 42,569,000 | 14.68% | 0.03% |
| Feb. 26, 2024 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 1431 | $20.27 | 81,726.0000 | 42,569,000 | 1.72% | 0.00% |
| Feb. 23, 2024 | Maney Rochelle L. | VP, Quality | A | Common Stock | 3366 | $0.00 | 40,382.0000 | 42,569,000 | 9.09% | 0.01% |
| Feb. 26, 2024 | Maney Rochelle L. | VP, Quality | S | Common Stock | 1168 | $20.27 | 39,214.0000 | 42,569,000 | 2.89% | 0.00% |
| Feb. 23, 2024 | Maney Rochelle L. | VP, Quality | A | Common Stock | 6418 | $0.00 | 45,632.0000 | 42,569,000 | 16.37% | 0.02% |
| Feb. 26, 2024 | Maney Rochelle L. | VP, Quality | S | Common Stock | 1114 | $20.27 | 44,518.0000 | 42,569,000 | 2.44% | 0.00% |
| Feb. 23, 2024 | Holloway Jean F | SVP, General Counsel | A | Common Stock | 5386 | $0.00 | 156,854.0000 | 42,569,000 | 3.56% | 0.01% |
| Feb. 26, 2024 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 1295 | $20.27 | 155,559.0000 | 42,569,000 | 0.83% | 0.00% |
| Feb. 23, 2024 | Holloway Jean F | SVP, General Counsel | A | Common Stock | 12836 | $0.00 | 168,395.0000 | 42,569,000 | 8.25% | 0.03% |
| Feb. 26, 2024 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 1543 | $20.27 | 166,852.0000 | 42,569,000 | 0.92% | 0.00% |
| Feb. 23, 2024 | GREEN ANDREW M | VP Regulatory | A | Common Stock | 3366 | $0.00 | 40,033.0000 | 42,569,000 | 9.18% | 0.01% |
| March 5, 2024 | Horton Amy | VP, Chief Accounting Officer | S | Common Stock | 1152 | $18.72 | 139,957.0000 | 42,569,000 | 0.82% | 0.00% |
| March 1, 2024 | Mackin James P | President & CEO | A | Common Stock | 28618 | $0.00 | 719,558.0000 | 42,569,000 | 4.14% | 0.07% |
| March 5, 2024 | Mackin James P | President & CEO | S | Common Stock | 13996 | $18.72 | 705,562.0000 | 42,569,000 | 1.95% | 0.03% |
| March 1, 2024 | Holloway Jean F | SVP, General Counsel | A | Common Stock | 5724 | $0.00 | 172,049.0000 | 42,569,000 | 3.44% | 0.01% |
| March 5, 2024 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 2380 | $18.72 | 169,669.0000 | 42,569,000 | 1.38% | 0.01% |
| March 1, 2024 | Davis John E | Chief Commercial Officer | A | Common Stock | 5724 | $0.00 | 167,659.0000 | 42,569,000 | 3.53% | 0.01% |
| March 5, 2024 | Davis John E | Chief Commercial Officer | S | Common Stock | 2022 | $18.72 | 165,637.0000 | 42,569,000 | 1.21% | 0.00% |
| March 1, 2024 | Getz Matthew A | VP, Human Resources | A | Common Stock | 3578 | $0.00 | 49,660.0000 | 42,569,000 | 7.76% | 0.01% |
| March 5, 2024 | Getz Matthew A | VP, Human Resources | S | Common Stock | 1157 | $18.72 | 48,503.0000 | 42,569,000 | 2.33% | 0.00% |
| March 1, 2024 | Maney Rochelle L. | VP, Quality | A | Common Stock | 3578 | $0.00 | 47,693.0000 | 42,569,000 | 8.11% | 0.01% |
| March 5, 2024 | Maney Rochelle L. | VP, Quality | S | Common Stock | 1157 | $18.72 | 46,536.0000 | 42,569,000 | 2.43% | 0.00% |
| March 1, 2024 | GREEN ANDREW M | VP Regulatory | A | Common Stock | 3578 | $0.00 | 47,701.0000 | 42,569,000 | 8.11% | 0.01% |
| March 5, 2024 | GREEN ANDREW M | VP Regulatory | S | Common Stock | 1160 | $18.72 | 46,541.0000 | 42,569,000 | 2.43% | 0.00% |
| March 1, 2024 | Stanton Marshall S. | SVP, Clinical & MD Affair | A | Common Stock | 5724 | $0.00 | 86,944.0000 | 42,569,000 | 7.05% | 0.01% |
| March 5, 2024 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 1506 | $18.72 | 85,438.0000 | 42,569,000 | 1.73% | 0.00% |
| March 1, 2024 | Horton Amy | VP, Chief Accounting Officer | A | Common Stock | 3578 | $0.00 | 141,109.0000 | 42,569,000 | 2.60% | 0.01% |
| Feb. 27, 2024 | Horton Amy | VP, Chief Accounting Officer | S | Common Stock | 325 | $19.83 | 137,531.0000 | 42,569,000 | 0.24% | 0.00% |
| Feb. 27, 2024 | Tyrs Florian | VP, Global Operations | S | Common Stock | 339 | $19.83 | 25,689.0000 | 42,569,000 | 1.30% | 0.00% |
| Feb. 27, 2024 | Mackin James P | President & CEO | S | Common Stock | 4837 | $19.83 | 690,940.0000 | 42,569,000 | 0.70% | 0.01% |
| Feb. 27, 2024 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 485 | $19.83 | 166,325.0000 | 42,569,000 | 0.29% | 0.00% |
| Feb. 27, 2024 | Davis John E | Chief Commercial Officer | S | Common Stock | 584 | $19.83 | 161,935.0000 | 42,569,000 | 0.36% | 0.00% |
| Feb. 27, 2024 | Maney Rochelle L. | VP, Quality | S | Common Stock | 370 | $19.83 | 44,115.0000 | 42,569,000 | 0.83% | 0.00% |
| Feb. 27, 2024 | Getz Matthew A | VP, Human Resources | S | Common Stock | 325 | $19.83 | 46,082.0000 | 42,569,000 | 0.70% | 0.00% |
| Feb. 27, 2024 | GREEN ANDREW M | VP Regulatory | S | Common Stock | 421 | $19.83 | 44,123.0000 | 42,569,000 | 0.95% | 0.00% |
| Feb. 27, 2024 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 465 | $19.83 | 81,220.0000 | 42,569,000 | 0.57% | 0.00% |
| Feb. 23, 2024 | Davis John E | Chief Commercial Officer | A | Common Stock | 5386 | $0.00 | 153,297.0000 | 42,569,000 | 3.64% | 0.01% |
| Feb. 23, 2024 | GREEN ANDREW M | VP Regulatory | A | Common Stock | 6914 | $0.00 | 45,762.0000 | 42,569,000 | 17.80% | 0.02% |
| Feb. 26, 2024 | GREEN ANDREW M | VP Regulatory | S | Common Stock | 1218 | $20.27 | 44,544.0000 | 42,569,000 | 2.66% | 0.00% |
| Feb. 23, 2024 | Stanton Marshall S. | SVP, Clinical & MD Affair | A | Common Stock | 5386 | $0.00 | 74,089.0000 | 42,569,000 | 7.84% | 0.01% |
| Feb. 26, 2024 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 1600 | $20.27 | 72,489.0000 | 42,569,000 | 2.16% | 0.00% |
| Feb. 23, 2024 | Stanton Marshall S. | SVP, Clinical & MD Affair | A | Common Stock | 10644 | $0.00 | 83,133.0000 | 42,569,000 | 14.68% | 0.03% |
| Feb. 26, 2024 | Stanton Marshall S. | SVP, Clinical & MD Affair | S | Common Stock | 1448 | $20.27 | 81,685.0000 | 42,569,000 | 1.74% | 0.00% |
| Feb. 23, 2024 | Horton Amy | VP, Chief Accounting Officer | A | Common Stock | 3366 | $0.00 | 133,604.0000 | 42,569,000 | 2.58% | 0.01% |
| Feb. 26, 2024 | Horton Amy | VP, Chief Accounting Officer | S | Common Stock | 1186 | $20.27 | 132,418.0000 | 42,569,000 | 0.89% | 0.00% |
| Feb. 23, 2024 | Horton Amy | VP, Chief Accounting Officer | A | Common Stock | 6418 | $0.00 | 138,836.0000 | 42,569,000 | 4.85% | 0.02% |
| Feb. 26, 2024 | Horton Amy | VP, Chief Accounting Officer | S | Common Stock | 980 | $20.27 | 137,856.0000 | 42,569,000 | 0.71% | 0.00% |
| Feb. 23, 2024 | Mackin James P | President & CEO | A | Common Stock | 40404 | $0.00 | 668,441.0000 | 42,569,000 | 6.43% | 0.09% |
| Feb. 26, 2024 | Mackin James P | President & CEO | S | Common Stock | 18144 | $20.27 | 650,297.0000 | 42,569,000 | 2.71% | 0.04% |
| Feb. 23, 2024 | Mackin James P | President & CEO | A | Common Stock | 58648 | $0.00 | 708,945.0000 | 42,569,000 | 9.02% | 0.14% |
| Feb. 26, 2024 | Mackin James P | President & CEO | S | Common Stock | 13168 | $20.27 | 695,777.0000 | 42,569,000 | 1.86% | 0.03% |
| Feb. 23, 2024 | Holloway Jean F | SVP, General Counsel | A | Common Stock | 5386 | $0.00 | 156,854.0000 | 42,569,000 | 3.56% | 0.01% |
| Feb. 26, 2024 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 1314 | $20.27 | 155,540.0000 | 42,569,000 | 0.84% | 0.00% |
| Feb. 23, 2024 | Holloway Jean F | SVP, General Counsel | A | Common Stock | 12836 | $0.00 | 168,376.0000 | 42,569,000 | 8.25% | 0.03% |
| Feb. 26, 2024 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 1566 | $20.27 | 166,810.0000 | 42,569,000 | 0.93% | 0.00% |
| Feb. 23, 2024 | Maney Rochelle L. | VP, Quality | A | Common Stock | 3366 | $0.00 | 40,382.0000 | 42,569,000 | 9.09% | 0.01% |
| Feb. 26, 2024 | Maney Rochelle L. | VP, Quality | S | Common Stock | 1185 | $20.27 | 39,197.0000 | 42,569,000 | 2.93% | 0.00% |
| Feb. 23, 2024 | Maney Rochelle L. | VP, Quality | A | Common Stock | 6418 | $0.00 | 45,615.0000 | 42,569,000 | 16.37% | 0.02% |
| Feb. 26, 2024 | Maney Rochelle L. | VP, Quality | S | Common Stock | 1130 | $20.27 | 44,485.0000 | 42,569,000 | 2.48% | 0.00% |
| Feb. 26, 2024 | Davis John E | Chief Commercial Officer | S | Common Stock | 1610 | $20.27 | 151,687.0000 | 42,569,000 | 1.05% | 0.00% |
| Feb. 23, 2024 | Davis John E | Chief Commercial Officer | A | Common Stock | 12736 | $0.00 | 164,423.0000 | 42,569,000 | 8.40% | 0.03% |
| Feb. 26, 2024 | Davis John E | Chief Commercial Officer | S | Common Stock | 1904 | $20.27 | 162,519.0000 | 42,569,000 | 1.16% | 0.00% |
| Feb. 23, 2024 | Getz Matthew A | VP, Human Resources | A | Common Stock | 3366 | $0.00 | 41,308.0000 | 42,569,000 | 8.87% | 0.01% |
| Feb. 26, 2024 | Getz Matthew A | VP, Human Resources | S | Common Stock | 1185 | $20.27 | 40,123.0000 | 42,569,000 | 2.87% | 0.00% |
| Feb. 23, 2024 | Getz Matthew A | VP, Human Resources | A | Common Stock | 7412 | $0.00 | 47,535.0000 | 42,569,000 | 18.47% | 0.02% |
| Feb. 26, 2024 | Getz Matthew A | VP, Human Resources | S | Common Stock | 1128 | $20.27 | 46,407.0000 | 42,569,000 | 2.37% | 0.00% |
| Feb. 23, 2024 | GREEN ANDREW M | VP Regulatory | A | Common Stock | 3366 | $0.00 | 40,033.0000 | 42,569,000 | 9.18% | 0.01% |
| Feb. 26, 2024 | GREEN ANDREW M | VP Regulatory | S | Common Stock | 1185 | $20.27 | 38,848.0000 | 42,569,000 | 2.96% | 0.00% |
| Feb. 26, 2024 | Tyrs Florian | VP, Global Operations | S | Common Stock | 893 | $20.27 | 26,065.0000 | 42,569,000 | 3.31% | 0.00% |
| Feb. 23, 2024 | Getz Matthew A | VP, Human Resources | A | Common Stock | 9250 | $0.00 | 37,942.0000 | 42,569,000 | 32.24% | 0.02% |
| Feb. 23, 2024 | GREEN ANDREW M | VP Regulatory | A | Common Stock | 11100 | $0.00 | 36,667.0000 | 42,569,000 | 43.42% | 0.03% |
| Feb. 23, 2024 | Holloway Jean F | SVP, General Counsel | A | Common Stock | 19610 | $0.00 | 151,468.0000 | 42,569,000 | 14.87% | 0.05% |
| Feb. 23, 2024 | Horton Amy | VP, Chief Accounting Officer | A | Common Stock | 7893 | $0.00 | 130,238.0000 | 42,569,000 | 6.45% | 0.02% |
| Feb. 23, 2024 | Berry Lance A | Executive VP, CFO | A | Common Stock | 37000 | $0.00 | 79,064.0000 | 42,569,000 | 87.96% | 0.09% |
| Feb. 23, 2024 | Maney Rochelle L. | VP, Quality | A | Common Stock | 7893 | $0.00 | 37,016.0000 | 42,569,000 | 27.10% | 0.02% |
| Feb. 23, 2024 | Stanton Marshall S. | SVP, Clinical & MD Affair | A | Common Stock | 14800 | $0.00 | 68,703.0000 | 42,569,000 | 27.46% | 0.03% |
| Feb. 23, 2024 | THOMSON ROBERT C | VP Research & Development | A | Common Stock | 8165 | $0.00 | 13,291.0000 | 42,569,000 | 159.29% | 0.02% |
| Feb. 23, 2024 | Tyrs Florian | VP, Global Operations | A | Common Stock | 6537 | $0.00 | 27,006.0000 | 42,569,000 | 31.94% | 0.02% |
| Feb. 23, 2024 | Davis John E | Chief Commercial Officer | A | Common Stock | 19734 | $0.00 | 147,911.0000 | 42,569,000 | 15.40% | 0.05% |
| Feb. 23, 2024 | Mackin James P | President & CEO | A | Common Stock | 89001 | $0.00 | 628,037.0000 | 42,569,000 | 16.51% | 0.21% |
| Feb. 20, 2024 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 1871 | $18.87 | 133,514.0000 | 42,569,000 | 1.38% | 0.00% |
| Feb. 20, 2024 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 1192 | $18.87 | 131,858.0000 | 42,569,000 | 0.90% | 0.00% |
| Feb. 20, 2024 | Horton Amy | VP, Chief Accounting Officer | S | Common Stock | 1329 | $18.87 | 122,711.0000 | 42,569,000 | 1.07% | 0.00% |
| Feb. 20, 2024 | Horton Amy | VP, Chief Accounting Officer | S | Common Stock | 366 | $18.87 | 122,345.0000 | 42,569,000 | 0.30% | 0.00% |
| Feb. 20, 2024 | Davis John E | Chief Commercial Officer | S | Common Stock | 2060 | $18.87 | 128,673.0000 | 42,569,000 | 1.58% | 0.00% |
| Feb. 20, 2024 | Davis John E | Chief Commercial Officer | S | Common Stock | 496 | $18.87 | 128,177.0000 | 42,569,000 | 0.39% | 0.00% |
| Feb. 20, 2024 | Maney Rochelle L. | VP, Quality | S | Common Stock | 407 | $18.87 | 29,123.0000 | 42,569,000 | 1.38% | 0.00% |
| Feb. 20, 2024 | Getz Matthew A | VP, Human Resources | S | Common Stock | 1329 | $18.87 | 29,058.0000 | 42,569,000 | 4.37% | 0.00% |
| Feb. 20, 2024 | Getz Matthew A | VP, Human Resources | S | Common Stock | 366 | $18.87 | 28,692.0000 | 42,569,000 | 1.26% | 0.00% |
| Feb. 20, 2024 | Tyrs Florian | VP, Global Operations | S | Common Stock | 249 | $18.87 | 19,174.0000 | 42,569,000 | 1.28% | 0.00% |
| Feb. 20, 2024 | Mackin James P | President & CEO | M | Common Stock | 59225 | $16.30 | 611,105.0000 | 42,569,000 | 10.73% | 0.14% |
| Feb. 20, 2024 | Mackin James P | President & CEO | S | Common Stock | 59225 | $18.85 | 551,880.0000 | 42,569,000 | 9.69% | 0.14% |
| Feb. 20, 2024 | Mackin James P | President & CEO | S | Common Stock | 10088 | $18.87 | 541,792.0000 | 42,569,000 | 1.83% | 0.02% |
| Feb. 20, 2024 | Mackin James P | President & CEO | S | Common Stock | 2756 | $18.87 | 539,036.0000 | 42,569,000 | 0.51% | 0.01% |
| Feb. 20, 2024 | Mackin James P | President & CEO | M | Stock Option(Right to Buy) | 59225 | $0.00 | 0.0000 | 42,569,000 | 100.00% | 0.14% |
| Feb. 20, 2024 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 464 | $18.87 | 133,050.0000 | 42,569,000 | 0.35% | 0.00% |
| June 30, 2023 | Holloway Jean F | SVP, General Counsel | A | Common Stock | 1393 | $10.30 | 134,913.0000 | 41,830,000 | 1.04% | 0.00% |
| Dec. 31, 2023 | Holloway Jean F | SVP, General Counsel | A | Common Stock | 472 | $14.61 | 135,385.0000 | 41,830,000 | 0.35% | 0.00% |
| June 30, 2023 | Stanton Marshall S. | SVP, Clinical & MD Affair | A | Common Stock | 1261 | $10.30 | 53,338.0000 | 41,830,000 | 2.42% | 0.00% |
| Dec. 31, 2023 | Stanton Marshall S. | SVP, Clinical & MD Affair | A | Common Stock | 565 | $14.61 | 53,903.0000 | 41,830,000 | 1.06% | 0.00% |
| June 30, 2023 | Davis John E | Senior VP, Global Sales | A | Common Stock | 2000 | $10.30 | 130,733.0000 | 41,830,000 | 1.55% | 0.00% |
| Jan. 2, 2024 | Holloway Jean F | SVP, General Counsel | M | Common Stock | 21229 | $16.30 | 154,749.0000 | 42,569,000 | 15.90% | 0.05% |
| Jan. 2, 2024 | Holloway Jean F | SVP, General Counsel | S | Common Stock | 21229 | $18.00 | 133,520.0000 | 42,569,000 | 13.72% | 0.05% |
| Jan. 2, 2024 | Holloway Jean F | SVP, General Counsel | M | Stock Option (Right to Buy) | 21229 | $16.30 | 0.0000 | 42,569,000 | 100.00% | 0.05% |
| Jan. 2, 2024 | Davis John E | Senior VP, Global Sales | M | Common Stock | 13562 | $16.30 | 142,295.0000 | 42,569,000 | 10.53% | 0.03% |
| Jan. 2, 2024 | Davis John E | Senior VP, Global Sales | S | Common Stock | 13562 | $18.00 | 128,733.0000 | 42,569,000 | 9.53% | 0.03% |
| Jan. 2, 2024 | Davis John E | Senior VP, Global Sales | M | Stock Option (Right to Buy) | 13562 | $16.30 | 0.0000 | 42,569,000 | 100.00% | 0.03% |